| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.81▲ | 1.80▲ | 1.80▲ | 1.78▲ | 2.04▼ |
| MA10 | 1.78▲ | 1.78▲ | 1.78▲ | 1.84▼ | N/A |
| MA20 | 1.79▲ | 1.80▲ | 1.81▲ | 1.96▼ | N/A |
| MA50 | 1.93▼ | 1.99▼ | 2.02▼ | N/A | N/A |
| MA100 | 2.04▼ | 2.02▼ | 2.16▼ | N/A | N/A |
| MA200 | 2.18▼ | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.017▲ | 0.017▲ | 0.015▲ | 0.113▲ | N/A |
| RSI | 50.699▲ | 48.765▼ | 47.510▼ | 26.678▼ | N/A |
| STOCH | 71.189 | 68.904 | 56.408 | 19.479▼ | N/A |
| WILL %R | -18.919▲ | -18.919▲ | -18.919▲ | -77.778▼ | N/A |
| CCI | 69.676 | 69.676 | 67.656 | -47.966 | N/A |
| CDL | $PPCB Doji Candlestick Pattern Detected | Set Alert |
|
Monday, September 22, 2025 04:20 AM
Detailed price information for Propanc Biopharma Inc (PPCB-Q) from The Globe and Mail including charting and trades.
|
|
Wednesday, September 17, 2025 05:50 AM
Propanc Biopharma (PPCB) announced that a certificate of grant for the Company’s “proenzyme composition” patent was received from the US Patent & ...
|
|
Wednesday, September 17, 2025 01:45 AM
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 03/10/25 | 1.84 | 1.84 | 1.84 | 1.84 | 11,902 |
| 02/10/25 | 1.70 | 1.87 | 1.70 | 1.84 | 298,000 |
| 01/10/25 | 1.69 | 1.75 | 1.68 | 1.70 | 109,263 |
| 30/09/25 | 1.77 | 1.83 | 1.69 | 1.70 | 144,600 |
| 29/09/25 | 1.80 | 1.92 | 1.80 | 1.83 | 62,733 |
| 26/09/25 | 1.81 | 1.8517 | 1.70 | 1.82 | 91,400 |
| 25/09/25 | 1.90 | 1.9124 | 1.78 | 1.81 | 210,177 |
| 24/09/25 | 1.90 | 2.0607 | 1.90 | 1.94 | 191,600 |
| 23/09/25 | 2.04 | 2.07 | 1.88 | 1.90 | 129,900 |
| 22/09/25 | 2.10 | 2.1358 | 1.95 | 2.04 | 201,300 |
|
|
||||
|
|
||||
|
|